Literature DB >> 2277273

Brain-stem auditory evoked potentials in multiple sclerosis: the relation to VEP, SEP and CSF immunoglobulins.

T Sand1, O Sjaastad, I Romslo, I Sulg.   

Abstract

One hundred patients with multiple sclerosis (MS) were analysed retrospectively with respect to investigations of brain-stem auditory evoked potentials (BAEP), pattern reversal visual evoked potentials (VEP), somatosensory evoked potentials (SEP), and cerebrospinal fluid immunoglobulins (CSF-IG). BAEP were abnormal in 42% of those with normal VEP and SEP examinations, and in 38% of patients with normal CSF-IG. The chance of obtaining at least one abnormal EP was lower in patients with normal CSF-IG than in patients with abnormal CSF. When a "dispersion ratio" was included in the criteria for BAEP abnormality, the sensitivity increased compared with conventional BAEP criteria. We recommend that BAEP should still be included in the EP test battery for patients with suspected MS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2277273     DOI: 10.1007/bf00315663

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  11 in total

1.  Multimodal evoked responses and cerebrospinal fluid oligoclonal immunoglobulins in patients with multiple sclerosis.

Authors:  T Ganes; N J Brautaset; R Nyberg-Hansen; B Vandvik
Journal:  Acta Neurol Scand       Date:  1986-05       Impact factor: 3.209

2.  The influence of click phase and rate upon latencies and latency distributions of the normal brain-stem auditory evoked potentials.

Authors:  T Sand; I Sulg
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1984-06

Review 3.  Overuse of evoked potentials: caution.

Authors:  A Eisen; R Q Cracco
Journal:  Neurology       Date:  1983-05       Impact factor: 9.910

4.  The diagnosis and classification of multiple sclerosis: evoked responses and spinal fluid electrophoresis.

Authors:  D R Bartel; O N Markand; O J Kolar
Journal:  Neurology       Date:  1983-05       Impact factor: 9.910

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Clinical correlates of abnormal brain-stem auditory evoked responses in multiple sclerosis.

Authors:  M Hutchinson; S Blandford; D Glynn; E A Martin
Journal:  Acta Neurol Scand       Date:  1984-08       Impact factor: 3.209

7.  Criteria for the clinical diagnosis of multiple sclerosis.

Authors:  A S Rose; G W Ellison; L W Myers; W W Tourtellotte
Journal:  Neurology       Date:  1976-06       Impact factor: 9.910

8.  Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis.

Authors:  C H Polman; J C Koetsier; E C Wolters
Journal:  Clin Neurol Neurosurg       Date:  1985       Impact factor: 1.876

9.  Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: disability, duration and age of onset.

Authors:  J E Olsson; H Link; R Müller
Journal:  J Neurol Sci       Date:  1976-02       Impact factor: 3.181

10.  A comparison of brainstem auditory evoked responses evoked by rarefaction and condensation stimulation in control subjects and in patients with Wernicke-Korsakoff syndrome and multiple sclerosis.

Authors:  S R Hammond; C Yiannikas; Y W Chan
Journal:  J Neurol Sci       Date:  1986-07       Impact factor: 3.181

View more
  2 in total

1.  Frequency doubling illusion VEPs and automated perimetry in multiple sclerosis.

Authors:  Rasa Ruseckaite; Teddy Maddess; Gytis Danta; Andrew Charles James
Journal:  Doc Ophthalmol       Date:  2006-08-12       Impact factor: 2.379

2.  Acute and long-term effects of adrenocorticotropin and dexamethasone on the auditory brainstem response in multiple sclerosis patients.

Authors:  J Born; B Schwab; R Schwab; H Schreiber
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.